XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.53

-2.8%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (17019)	7/7/2004 10:57:56 PM
From: Bluegreen	of 17367

So, how do you like this?>>>>>>During an analyst meeting held by Chiron Corporation on June 23rd, Chiron announced the first monoclonal antibody target for cancer, CD40, that it will co-develop with XOMA. XOMA and Chiron entered into a multi-product collaboration agreement in February of 2004 for the development and commercialization on antibody products for the treatment of cancer. Chiron and XOMA plan to file an Investigational New Drug (IND) application to the U.S. FDA for the anti-CD40mAb compound by the end of 2004. On July 6th, Chiron announced the acquisition of Sagres Discovery, a privately held discovery stage company based in Davis, California, that specializes in the discovery and validation of oncology targets. Under the acquisition, Chiron reportedly will have access to all of Sagres' proprietary technology in the area of oncology. Further review of these targets is expected to identify additional antibody target candidates that will be used as part of XOMA's and Chiron's antibody product candidate program for the treatment of cancer.<<<<<<<<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next